Jounce Therapeutics (JNCE) Reports Q2 Loss of $0.14/Share

Jounce Therapeutics (NASDAQ: JNCE) reported Q2 EPS of ($0.14), versus ($0.11) reported last year. Revenue for the quarter came in at $19.38 million versus the consensus estimate of $12.91 million.

For earnings history and earnings-related data on Jounce Therapeutics (JNCE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79